You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥-B(02137.HK)在2025 EASL會議上以最新突破海報的形式公佈其正在進行的ENSURE 2期研究數據

格隆匯5月8日丨騰盛博藥-B(02137.HK)發佈公告,公司在荷蘭阿姆斯特丹舉行的2025年歐洲肝病研究協會 (EASL)會議上以最新突破海報的形式公佈其正在進行的ENSURE 2期研究數據。

ENSURE(NCT05970289)是一項多中心、開放性2期研究。隊列1-3旨在評估elebsiran,一種研究性小幹擾核糖核酸(“siRNA”)在與聚乙二醇幹擾素α(“PEG-IFNα”)聯合治療基線乙肝表面抗原(“HBsAg”)水平爲100-3,000 IU/mL慢性乙型肝炎病毒(“HBV”)感染者中的作用。

公司首席醫學官David Margolis博士表示:“ENSURE研究隊列4的數據令人鼓舞。我們在目標人羣中發現,經過BRII-179預治療產生免疫應答的患者在實現較高的HBsAg血清清除率方面表現出顯著優勢。藉助BRII-179,我們可以識別內在免疫受損程度較低的患者,並進一步增強其免疫應答。這種方法可使HBsAg清除更持久,並有可能縮短PEG-IFNα的治療時間。我們正在全速推進臨牀工作,以期爲慢性乙型肝炎患者提供有意義的可選方案。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account